OMNIAB INC (OABI)
Health Care · biotechnology / drug discovery technology · NASDAQ
OmniAb is an antibody discovery technology leader that provides pharmaceutical partners with proprietary transgenic animal platforms, AI-driven screening, and bioinformatics tools to accelerate the creation of therapeutic biologics.
What OMNIAB INC does
OmniAb is a biotechnology company that licenses proprietary discovery platforms to pharmaceutical and biotech partners for the development of next-generation therapeutic antibodies. Its platform utilizes engineered transgenic animals, artificial intelligence, and high-throughput screening technologies to identify diverse human antibody candidates for complex biological targets. The company's business model generates revenue through access fees, research services, development milestones, and future commercial royalties.
Recent developments
The company raised its full-year 2026 revenue and cash outlook due to business momentum. It also recently appointed Amechi Nwachuku as Chief Operating Officer.
From OMNIAB INC's filing of 2026-08-06.
Themes: antibody discovery, AI-powered drug discovery, biologics development, transgenic animal platforms, therapeutic antibodies
Fundamentals
- Price$4.92 as of 2026-10-21 close
- Market cap$715M as of 2026-07-30 (share count; price 2026-10-21)
- 1-year return+196.1% 2025-10-21 close $1.66 → 2026-10-21 close $4.92
- P/En/a negative earnings
- Net margin-347.0% FY2025, SEC XBRL
- ROE-24.3% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)-29.3% FY2025, SEC XBRL
- Revenue CAGR (3y)-31.9% SEC XBRL
- Beta1.01 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
Dividend: at least 1 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How OABI compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $13M | -$7M | -$6M | -$0.05 | $3M† | $110000† |
| Q1 FY2026 2026-03-31 | $14M | -$8M | -$8M | -$0.06 | -$5M | $167000 |
| Q4 FY2025 2025-12-31 | $8M† | -$16M† | -$14M† | -$0.11† | -$6M† | $9000† |
| Q3 FY2025 2025-09-30 | $2M | -$18M | -$17M | -$0.14 | -$10M† | $182000† |
| Q2 FY2025 2025-06-30 | $4M | -$16M | -$16M | -$0.15 | -$5M† | $165000† |
| Q1 FY2025 2025-03-31 | $4M | -$19M | -$18M | -$0.17 | -$16M | $209000 |
| Q4 FY2024 2024-12-31 | $11M† | -$16M† | -$13M† | -$0.13† | -$4M† | $46000† |
| Q3 FY2024 2024-09-30 | $4M | -$20M | -$16M | -$0.16 | -$7M† | $152000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$24M
- Short-term investments$28M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How OMNIAB INC looks technically
OMNIAB INC (OABI) is trading 89.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 98 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 35 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 3% of the past ~6 months), which often precedes a bigger move. Trading volume is running unusually high — about 2.5× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 89.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +89.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.49 | $4.49 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.59 | $2.59 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 19 calendar days ago — the swings before that are what the structure reading is measured on | 19 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 5.09. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 98 trading days ago — a "golden cross", a bullish long-term signal | 98 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with buyers in control | 28.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 57.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($4.21 to $5.13) — its "stochastic" reading is 76 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 76.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 33 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.43 | $5.43 |
|---|---|---|
| From the 52-week high | it is 9.5% below its 52-week high (its highest price of the past year) | -9.5% |
| Above the 52-week low | it is 272.3% above its 52-week low (its lowest price of the past year) | +272.4% |
| Below the 52-week high | it is 9.5% below its highest point of the past year | 9.5% |
| Since a 20-day breakout | it made a new 20-day high about 35 trading days ago | 35 sessions |
| Since a 55-day breakout | it made a new 55-day high about 35 trading days ago | 35 sessions |
| All-time high | its highest closing price on record is $6.71 (set on 2024-01-09) | $6.71 |
| Given back of the 52-week move | over the past year its closes ranged ($1.36 to $5.04), and it has given back only a small part of its rise from last year’s low — 3% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.65 to $2.77. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 3.4% |
| From the all-time high | it is 26.8% below its all-time high | -26.8% |
| Nearest price level | it is trading 14.8% above a support level at $4.19 — a price it turned at twice since 2024-11-26, most recently on 2024-12-09. Since 2024-10-21 it has 11 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -14.8% |
| All-time low | its lowest closing price on record is $1.22 (set on 2025-05-30) | $1.22 |
| Above the all-time low | it is 302.9% above its all-time low | +302.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 3% of the past ~6 months), which often precedes a bigger move | 3rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3174 between its high and its low — about 6.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3174 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.42 and $5.07 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.42 – $4.74 – $5.07 |
| Typical daily range (% of price) | its price moves about 6.5% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.5% |
| Stretch from the 200-day average | it is trading 7.3 daily ranges above its 200-day average price (89.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.5× its 30-day average, a sign of heightened interest | 2.51× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bearish engulfing | 3 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-21 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 23.8% above the previous close 46 sessions ago and has not traded back through the level it left behind at 3.38 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +23.8% |
| Gap filled | a 3.3% gap down opened on 2026-10-08 has been "filled" 9 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 9 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 7.4 percentage points (the stock gained 7.3% while the market lost 0.1%) | +7.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 131.9 percentage points (the stock gained 135.2% while the market gained 3.3%) | +131.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 222.3 percentage points (the stock gained 232.1% while the market gained 9.8%) | +222.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 180.9 percentage points (the stock gained 196.1% while the market gained 15.2%) | +180.9% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 15.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +10.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 49% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $3.30 — a volume-weighted average of daily closes over 197 sessions, not a true tick-by-tick VWAP. | +48.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 14% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $4.32 — a volume-weighted average of daily closes over 54 sessions, not a true tick-by-tick VWAP. | +13.8% |
Double top, bearish — forming · entry $3.95 · 34 sessions in
Price levels it has turned at before
OABI last closed at $4.92 on 2026-10-21. Since 2024-10-21 it has turned at 11 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.19 | Support | 14.8% below the last close | turned there twice · 2024-11-26 to 2024-12-09 |
| $3.44 | Support | 30.1% below the last close | turned there twice · 2024-12-19 to 2025-01-27 |
| $2.23 | Support | 54.7% below the last close | turned there twice · 2025-03-20 to 2025-12-12 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $5.09.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 4 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 9 trading days, since 2026-10-09.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · Unusually heavy trading volume · in a Bollinger Band volatility squeeze · in a strong, established uptrend (ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · breakout · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$8.33 range $5.00 – $12.00; median $8.00
Analyst estimates, as of 2026-10-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for OABI
- Consensus EPS estimate-$0.13 next reporting period, as of 2026-10-18
- Estimate change, 30 days$0.00 from -$0.13, on 2026-09-13, 35-day window
- Readings revised upward0% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy dependence on the commercial success, development timelines, and regulatory outcomes of products developed by third-party partners.","Potential impact of healthcare reform and drug pricing legislation, such as the Inflation Reduction Act, on the pharmaceutical industry and demand for the company's technologies.","Unprofitable operating history with risks associated with maintaining sufficient cash runway and capital to fund operations."]
What changed in the latest 10-Q
AI-assisted comparison of OABI's 10-Q filed 2026-05-07 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 'year ended December 31, 2025' and '2025 Annual Report' (newer filing, filed 2026-05-07)
- As of March 31, 2026: 107 active partners with 409 active programs, 27 OmniAb-derived antibodies in clinical development, two under regulatory review (newer filing, filed 2026-05-07)
- Addition of 'peptides and many others' to list of therapeutic modalities (newer filing, filed 2026-05-07)
- Removed:
- Reference to 'year ended December 31, 2024' and '2024 Annual Report' (older filing, filed 2025-11-04)
- As of September 30, 2025: 104 active partners with 399 active programs, 28 OmniAb-derived antibodies in clinical development, one under regulatory review (older filing, filed 2025-11-04)
- Text ending with 'and many others.' without 'peptides' explicitly listed (older filing, filed 2025-11-04)
- Reworded:
- Date reference changed from 'September 30, 2025' to 'March 31, 2026' for active partner metrics
- Partner count changed from '104 active partners' to '107 active partners'
- Active programs changed from '399 active programs' to '409 active programs'
- Clinical development antibodies changed from '28' to '27'
- Regulatory review products changed from 'one under regulatory review' to 'two under regulatory review'
- Therapeutic modalities list expanded to include 'peptides' before 'and many others'
- Notes:
- Text appears truncated at end of both versions ('in which c' and 'in which case,' respectively), preventing full comparison of final sentence
- Page number differs (23 vs 24) but this is formatting, not content change
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-17. The 5 days since 2026-10-17 have not been checked yet.
Most recent open-market transaction: 2026-04-07. Based on Form 4 filings read through 2026-10-17; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about OABI's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding OABI as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 12,014,987
- Reported value $29,556,869
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about OABI's institutional holders → See what each manager we track holds →
Short interest (FINRA)
OABI had 8,198,042 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
OABI had 5.64% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.75 days to cover at the same settlement.
- Reported short interest (shares) 8,198,042
- Short interest (% of shares outstanding) 5.64%
- Prior settlement (shares) 7,125,743
- Reported change 15.05%
- Days to cover (reported) 6.75
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AbCellera Biologics (ABCL)
- Twist Bioscience (TWST)
- Charles River Laboratories (CRL)
- Eurofins Scientific (ERFSF)
- WuXi AppTec (WUXIF)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare OABI vs…
OABI ranks in…
Frequently asked questions
What does OMNIAB INC (OABI) do?
OmniAb is a biotechnology company that licenses proprietary discovery platforms to pharmaceutical and biotech partners for the development of next-generation therapeutic antibodies. Its platform utilizes engineered transgenic animals, artificial intelligence, and high-throughput screening technologies to identify diverse human antibody candidates for complex biological targets.
What sector is OMNIAB INC (OABI) in?
OMNIAB INC (OABI) is classified in the Health Care sector. Its industry is biotechnology / drug discovery technology. It trades on NASDAQ.
Who are OMNIAB INC's (OABI) competitors?
Notable peers of OMNIAB INC (OABI) include AbCellera Biologics, Twist Bioscience, Charles River Laboratories, Eurofins Scientific and WuXi AppTec. This peer set is informational only — not financial advice.
Is OMNIAB INC (OABI) overbought or oversold right now?
OMNIAB INC (OABI) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on OABI come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.